[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352874-105":59,"doc-detail-352874-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","egfr-targeted-affibodypolyic-polyplex-kills-egfr-overexpressing-cancer-cells-without-activating-the-egfr","EGFR-targeted affibody–polyIC polyplex kills EGFR-overexpressing cancer cells without activating the EGFR","","The epidermal growth factor receptor (EGFR) is aberrantly activated in many human epithelial cancers. The study reports preparation, purification, and anticancer potency of an anti-EGFR affibody ZEGFR 1907’-polyethylenimine–polyIC complex (PPEA-polyplex). Surface plasmon resonance showed tight binding to full-length soluble EGFR with KD 6.74 nM. The complex does not activate EGFR kinase, yet kills tumor cells with medium-to-high EGFR, induces chemotactic cytokine release, and enables PBMC-mediated bystander killing. It also suppresses A431 xenografts in nude mice and indicates broader potential against EGFR-overexpressing tumors.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/egfr-targeted-affibodypolyic-polyplex-kills-egfr-overexpressing-cancer-cells-without-activating-the-egfr/352874/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/egfr-targeted-affibodypolyic-polyplex-kills-egfr-overexpressing-cancer-cells-without-activating-the-egfr/352874.png","ImageObject",300,407,{"name":92,"@type":93},"Aditya","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main therapeutic concept tested in this study?","Question",{"text":112,"@type":113},"An EGFR-targeted affibody–polyIC polyplex (PPEA-polyplex) is used to selectively kill EGFR-overexpressing cancer cells without activating EGFR kinase.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was EGFR binding affinity assessed and what was the result?",{"text":117,"@type":113},"Surface plasmon resonance analysis showed the ZEGFR 1907’ affibody binds tightly to full-length soluble EGFR with an average equilibrium dissociation constant (KD) of 6.74 nM.",{"name":119,"@type":110,"acceptedAnswer":120},"Does the PPEA-polyplex activate EGFR kinase, and what anticancer effects were observed instead?",{"text":121,"@type":113},"The PPEA-polyplex does not activate EGFR kinase. Instead, it kills EGFR-expressing tumor cells, promotes cytokine release, and supports PBMC-mediated bystander killing, with inhibition of A431 xenograft growth in immunocompromised mice.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352874,1790935423,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085564549,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","OPEN ACCESS  \nCitation: Pettikiriarachchi A, Ugolev Y, Birkinshaw R, Wardak A, Faux MC, Adams TE, et al. (2026) EGFR-targeted affibody–polyIC polyplex kills EGFR-overexpressing cancer cells without activating the EGFR. PLoS One 21(5): e0334584. [https://doi.org/10.1371/journal](https://doi.org/10.1371/journal). pone.0334584  \nEditor: Hamidreza Montazeri Aliabadi, Chapman University, UNITED STATES OF AMERICA Received: October 6, 2025  \nAccepted: April 14, 2026  \nPublished: May 5, 2026  \nPeer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: [https://doi.org/10.1371/journal](https://doi.org/10.1371/journal). pone.0334584  \nCopyright: © 2026 Pettikiriarachchi et al. This is an open access article distributed under the terms of the Creative Commons Attribution  License, which permits unrestricted use,  \nRESEARCH ARTICLE  \nEGFR-targeted affibody–polyIC polyplex kills EGFR-overexpressing cancer cells without activating the EGFR  \nAnne Pettikiriarachchi1,2☯‡, Yelena Ugolev3☯‡, Richard Birkinshaw2, Ahmad Wardak2, Maree C. Faux1,2, Timothy E. Adams4, Salim Joubran3, Alexei Shir3, Nufar Edinger3, Maya Zigler3, Alexander Levitzki3, Antony W. Burgess1,2,5*  \n1 Personal Oncology, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia, 2 Structural Biology, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia, 3 Unit of Cellular Signaling, Silberman Life Sciences Institute, The Hebrew University of Jerusalem, Jerusalem, Israel,  \n4 CSIRO Manufacturing, Clayton, Victoria, Australia, 5 Department of Surgery (RMH), University of Melbourne, Parkville, Australia  \n☯ These authors contributed equally to this work.  \n‡ These authors share first authorship for this work.  \n* [tburgess@wehi.edu.au](tburgess@wehi.edu.au)  \nAbstract  \nThe epidermal growth factor receptor (EGFR) is aberrantly activated in many human epithelial cancers. This report presents the preparation, purification, and the anticancer potency of an anti-EGFR affibody (ZEGFR 1907’)-polyethylenimine (PEI)-polyIC complex (PPEA-polyplex) . Surface plasmon resonance analysis showed that the ZEGFR 1907’ affibody binds tightly to full-length sEGFR with an average equilibrium dissociation constant, KD, value of 6.74 nM. As expected the PPEA-polyplex does not activate the EGFR kinase, but kills tumor cells expressing medium to high levels of EGFR. The PPEA-polyplex stimulates the release of chemotactic cytokines (e.g. , GRO-α , IFN-γ–inducible protein-10) and promoted PBMC-mediated bystander killing of non-treated tumor cells. The PPEA-polyplex also inhibited the growth of humanepidermoid vulval carcinoma (A431) xenografts growing in immunocompromised nude mice. Both the in vitro and in vivo results indicate that PPEA-polyplexes have the potential to inhibit the growth of tumors which over-express the EGFR, including colon and breast cancer cells.  \nIntroduction  \nThe epidermal growth factor receptor (EGFR) was identified as a target for cancer therapy almost forty years ago [ 1] . Over 70% of malignant tumors have abnormal expression or activation of the EGFR, including brain [2], bladder [3], colorectal [4 ,5], head and neck [6], lung [7] and breast cancers [8] . Cancers can be driven by autocrine activation of the receptor [9 , 10], mutation [ 11] or amplification [ 12] of the EGFR gene. This perturbation of EGFR signaling homeostasis plays a critical role  \nPLOS One | [https://doi.org/10.1371/journal.pone.0334584](https://doi.org/10.1371/journal.pone.0334584) May 5, 2026 1 / 28  \ndistribution, and reproduction in any medium, provided the original author and source are credited.  \nData availability statement: All relevant data are within the paper and its Supporting  information files.  \nFunding: The author(s) received no sp","cbCaihj1zGiZamn9","https://ap.wps.com/l/cbCaihj1zGiZamn9","pdf",2053583,28,"English","# Abstract\n## Introduction\n## Background and rationale","[{\"question\":\"What is the main therapeutic concept tested in this study?\",\"answer\":\"An EGFR-targeted affibody–polyIC polyplex (PPEA-polyplex) is used to selectively kill EGFR-overexpressing cancer cells without activating EGFR kinase.\"},{\"question\":\"How was EGFR binding affinity assessed and what was the result?\",\"answer\":\"Surface plasmon resonance analysis showed the ZEGFR 1907’ affibody binds tightly to full-length soluble EGFR with an average equilibrium dissociation constant (KD) of 6.74 nM.\"},{\"question\":\"Does the PPEA-polyplex activate EGFR kinase, and what anticancer effects were observed instead?\",\"answer\":\"The PPEA-polyplex does not activate EGFR kinase. Instead, it kills EGFR-expressing tumor cells, promotes cytokine release, and supports PBMC-mediated bystander killing, with inhibition of A431 xenograft growth in immunocompromised mice.\"}]","EGFR-targeted affibody–polyIC polyplex kills EGFR-overexpressing cancer cells without activating the EGFR | PDF",1790101823,71,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a136ad289751a2258a615e55cfe6e81b.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/32ea24ea497dfc34814965e600905650.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/73a6e66687e3a9f7b623f322416a8756.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e2e68d89d6d045bcaa11b9bde3f5683d.webp",980,1268]